Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:RNLX Renalytix (RNLX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsHeadlinesOwnershipShort InterestTrends About Renalytix Stock (NASDAQ:RNLX) 30 days 90 days 365 days Advanced Chart Ad WealthPressBreaking News: Tesla headed to $500…That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. Get Renalytix alerts:Sign Up Key Stats Today's Range$0.19▼$0.2350-Day Range$0.18▼$0.3052-Week Range$0.18▼$2.40Volume934,400 shsAverage Volume1.45 million shsMarket Capitalization$17.18 millionP/E RatioN/ADividend YieldN/APrice Target$3.00Consensus RatingBuy Company OverviewRenalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix Plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; and Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is based in New York, New York.Read More… Breaking News: Tesla headed to $500… (Ad)That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. Receive RNLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Renalytix and its competitors with MarketBeat's FREE daily newsletter. Email Address RNLX Stock News HeadlinesRenalytix Adjusts Share Capital Amid Fundraising ShortfallNovember 6, 2024 | markets.businessinsider.comRenalytix and Steno Diabetes Center Announce Precision Medicine Collaboration Marking First Expansion for KidneyIntelX Platform Beyond USJuly 11, 2024 | globenewswire.com2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.November 21, 2024 | Darwin (Ad)Renalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting DeterminationJune 27, 2024 | globenewswire.comMedicare Issues Final Coverage Determination for kidneyintelX.dkdJune 14, 2024 | globenewswire.comRNLX Stock Earnings: Renalytix Misses EPS, Misses Revenue for Q3 2024May 15, 2024 | investorplace.comRenalytix AI GAAP EPS of -$0.08 beats by $0.01, revenue of $0.54M misses by $0.56MMay 15, 2024 | msn.comRenalytix Reports Financial Results for Third Quarter of Fiscal Year 2024May 15, 2024 | globenewswire.comSee More Headlines RNLX Stock Analysis - Frequently Asked Questions How were Renalytix's earnings last quarter? Renalytix Plc (NASDAQ:RNLX) posted its earnings results on Tuesday, November, 14th. The company reported ($0.11) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.11). The business earned $0.46 million during the quarter, compared to analysts' expectations of $0.70 million. When did Renalytix IPO? Renalytix (RNLX) raised $156 million in an IPO on Friday, July 17th 2020. The company issued 11,000,000 shares at $14.22 per share. J.P. Morgan and Stifel acted as the underwriters for the IPO. Who are Renalytix's major shareholders? Renalytix's top institutional shareholders include Stifel Financial Corp (0.59%). What other stocks do shareholders of Renalytix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Renalytix investors own include Invesco QQQ (QQQ), SPDR Dow Jones Industrial Average ETF Trust (DIA), SPDR S&P 500 ETF Trust (SPY), NVIDIA (NVDA), CrowdStrike (CRWD), Broadcom (AVGO) and Meta Platforms (META). Company Calendar Last Earnings11/14/2023Today11/21/2024Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorComputer and Technology Industry Medical laboratories Sub-IndustryHealthcare Current SymbolNASDAQ:RNLX CUSIPN/A CIK1811115 Webwww.renalytixai.com Phone44-20-3139-2910FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Stock Price Target$3.00 High Stock Price Target$3.00 Low Stock Price Target$3.00 Potential Upside/Downside+1,348.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-33,460,000.00 Net Margins-1,461.60% Pretax Margin-1,461.42% Return on EquityN/A Return on Assets-281.40% Debt Debt-to-Equity RatioN/A Current Ratio0.53 Quick Ratio0.53 Sales & Book Value Annual Sales$2.29 million Price / Sales7.50 Cash FlowN/A Price / Cash FlowN/A Book Value($0.10) per share Price / Book-2.07Miscellaneous Outstanding Shares82,960,000Free Float63,059,000Market Cap$17.18 million OptionableOptionable Beta2.72 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report This page (NASDAQ:RNLX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Renalytix Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Renalytix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.